Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 10 of 58, showing 10 Applications out of 576 total, starting on record 91, ending on 100

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

91.

ECCT/15/02/05  
    An open-label clinical trial to assess the pharmacokinetics and safety of miltefosine allometric dose for the treatment of children with primary visceral leishmaniasis in Eastern Africa   
Principal Investigator(s)
1. Rashid Juma
Site(s) in Kenya
1. Kimalel Health Centre (Baringo county)
2. Kacheliba District Hospital (West Pokot county)
 
09-04-2015 View

92.

ECCT/15/03/01   A phase III, non-inferiority trial using Carbetocin room temperature stable (RTS) for the prevention of postpartum haemorrhage during the third stage of labour in women delivering
    A phase III, randomized, double-blind, active, controlled, multinational, multicentre,  non-inferiority trial using Carbetocin room temperature stable (RTS) for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally.   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
Kenyatta National Hospital
 
27-07-2015 View

93.

ECCT/15/04/02  
    Plasma concentration profiles after oral  administration of oleylphosphocholine tablet  formulation: safety, tolerability and pharmacokinetics  of 100 mg single dose in healthy male volunteers.   
Principal Investigator(s)
1. Ravasco Rashid Juma
Site(s) in Kenya
KEMRI
 
15-06-2015 View

94.

ECCT/15/05/01   Janssen Ebola vaccine study
    A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa   
Principal Investigator(s)
1. Prof Omu Aggrey Anzala
Site(s) in Kenya
KAVI –Institute of Clinical Research
 
17-12-2015 View

95.

ECCT/15/05/02  
    The TRIO Study: Acceptability of Different Multipurpose Prevention Technology (MPT) Delivery Methods (Placebo)   
Principal Investigator(s)
1. Kawango Agot
Site(s) in Kenya
Tuungane Youth Center Clinic
 
13-10-2015 View

96.

ECCT/15/06/01  
    Pyronaridine-artesunate and artemether-lumefantrine for the treatment of paediatric uncomplicated falciparum malaria in Western Kenya   
Principal Investigator(s)
1. Patrick Sawa
Site(s) in Kenya
St. Judes Clinic, ICIPE
 
04-09-2015 View

97.

ECCT/15/06/02   ZINC in Sickle cell study
    The effects of Zinc supplementation in children with sickle cell disease in Western Kenya: a pilot study.   
Principal Investigator(s)
1. Lucas Otieno Tina
Site(s) in Kenya
Health Facilities in Western Kenya
 
17-08-2015 View

98.

ECCT/15/06/03   DolutegrAvir With NRTIs as second-line treatment (DAWNING)
    A Phase 3b, randomised, open-label study of the antiviral activity and safety of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy   
Principal Investigator(s)
1. Dr. Evans Inyangala Amukoye
2. Dr. Maricianah Atieno Onono
Site(s) in Kenya
1. Center for Respiratory Diseases Research, CRDR, KEMRI, Nairobi (Nairobi City county)
2. KEMRI-Research Care and Training Program (RCTP), Family AIDS Care and Education Services (FACES), Lumumba health centre (Kisumu county)
 
29-07-2015 View

99.

ECCT/15/06/04   A5316
        A5316           Evaluating Pharmacokinetic Interactions with Vaginal Ring Contraceptives and Antiretroviral Therapy   
Principal Investigator(s)
1. Dr. Esther Mumbi Makanga Makanga
2. Dr. Victor Akelo Akelo
3. Dr.Victor O. Mudhune Mudhune
4. Dr. Kevin P. Cain Cain
Site(s) in Kenya
KEMRI- CDC
 
17-07-2015 View

100.

ECCT/15/08/01   Rifapentine During Intensive Phase TB Treatment
     Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: a randomized, open-label, controlled, phase 3 clinical trial   
Principal Investigator(s)
1. Elisha Ochieng Okeyo
Site(s) in Kenya
KEMRICDC, KISUMU, KENYA
 
05-05-2016 View